• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Incorporating the patient voice into your trial requires thoughtful consideration of how you measure the patient experience. 

How, when and where you collect PROs can have a significant impact on patient burden. Collecting PROs in a way that is easy and convenient for them enhances patient satisfaction and keeps the focus where it truly belongs – on the patient.

Speak to a Clario Scientist to discuss how to make your oncology trial patient focused. 

How to design a patient-centric oncology trial using your PRO strategy

Here are some key areas to consider when designing your oncology trial: 

  • Understand the patient experience: include a range of PROs that measure physical and role function, symptomatic adverse events, and tumor-related symptoms 
  • Minimize repetitive questions and focus on what’s most important to reduce burden 
  • Allow patients to let you know how they’re feeling, when they’re feeling it. Collect PROs at the appropriate frequency and ‘in the moment’ 
  • Enable patients to use ePROs at home to increase frequency of symptom reporting without the travel burden   
  • Shorten their time at site with patients completing PROs at home before their visit 
  • Keep patients informed about the trial and their role with notifications, messages and reminders, disease specific information, and motivational training 

Download our free guide on what really matters to oncology patients and how to reduce patient burden.

Clario’s oncology experience

3k

Oncology trials

110k

Sites

500k

Patients

85

Drug approvals

Clario has a world-class Science team to ensure you have the right PRO strategy

Our Science team will advise you on the right PRO strategy which will simplify your trial for your oncology patients.

  • We advise in areas such as choice of ePRO assessments, frequency of PRO administration, choice of electronic devices, and study design considerations.
  • We ensure you’re collecting sufficient patient symptoms to capture high quality data and differentiate your drug, while also simplifying participation and driving patient engagement and compliance. 

Bryan McDowell headshot

Bryan McDowell, MSc, MBA

VP, eCOA Science and Consulting

Lindsay Hughes headshot

Lindsay Hughes, PhD, MS

Director, eCOA Science and Consulting

Laura Khurana headshot

Laura Khurana, MPH

Principal Scientific Advisor

Kelly Dumais, PhD

Principal Scientific Advisor